Does Rallies show 13F holders for ANAB?

Yes. Rallies tracks hedge fund and 13F ownership data for ANAB, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ANAB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ANAB. It does not provide personalized investment advice.

ANAB (AnaptysBio, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

AnaptysBio, Inc. Common Stock (ANAB) is a publicly traded Healthcare sector company. As of May 21, 2026, ANAB trades at $60.06 with a market cap of $1.71B and a P/E ratio of -64.24. ANAB moved +0.50% today. Year to date, ANAB is +39.07%; over the trailing twelve months it is +184.74%. Its 52-week range spans $12.21 to $73.30. Analyst consensus is strong buy with an average price target of $81.27. Rallies surfaces ANAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ANAB stock?

Hedge funds tracked by Rallies that own ANAB include Panagora Asset and Mangrove Partners. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for AnaptysBio, Inc. Common Stock.

ANAB Key Metrics

Key financial metrics for ANAB
Metric	Value
Price	$60.06
Market Cap	$1.71B
P/E Ratio	-64.24
EPS	$-0.94
Dividend Yield	0.00%
52-Week High	$73.30
52-Week Low	$12.21
Volume	135
Avg Volume	0
Revenue (TTM)	$232.39M
Net Income	$-26.79M
Gross Margin	0.00%

Top Hedge Funds Holding ANAB

Panagora Asset holds 20.87K shares of ANAB, changed -67.31% as of Dec 31, 2025.
Mangrove Partners holds 3.71K shares of ANAB, changed -99.46% as of Mar 31, 2026.

Latest ANAB News

AnaptysBio Spin-Off Spurs 14.8% Rally as Jemperli Royalty Model Debuts — May 1, 2026
AnaptysBio Spin-Off Yields $140M Cash and >95% EBIT Margin — Apr 20, 2026
Anaptys approves $100M buyback and First Tracks $180M spin-off — Mar 27, 2026
AnaptysBio to Separate RoyaltyCo Holding Jemperli Rights and Biopharma Unit with $310M Cash — Mar 4, 2026
AnaptysBio Q4 EPS Rises to $1.58, Revenues Jump 151% to $108M — Mar 3, 2026

Recent ANAB Insider Trades

Schmid John P. sold 12.60K (~$701.71K) on Mar 30, 2026.
Schmid John P. sold 7.53K (~$426.78K) on Mar 30, 2026.
Schmid John P. sold 522 (~$29.96K) on Mar 30, 2026.

ANAB Analyst Consensus

11 analysts cover ANAB: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $81.27.

Common questions about ANAB

Who owns ANAB stock?: Hedge funds tracked by Rallies that own ANAB include Panagora Asset and Mangrove Partners. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for AnaptysBio, Inc. Common Stock.
Does Rallies show 13F holders for ANAB?: Yes. Rallies tracks hedge fund and 13F ownership data for ANAB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ANAB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ANAB. It does not provide personalized investment advice.